Answers are grounded in this paper and cite their sources.
Balovaptan, an antagonist of the vasopressin system, has been shown to be a drug with potential to treat the main symptoms of Autism Spectrum Disorder (ASD). The objective of this work was to gather and analyze information already published about the mechanism of action, clinical trials, dosage information, pharmacokinetics, and safety profile of balovaptan, bringing an update on the current situation of this molecule in ASD.
No takes yet. Share an insight, caveat, or question.
da et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: